ATE309207T1 - Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren - Google Patents

Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren

Info

Publication number
ATE309207T1
ATE309207T1 AT00961360T AT00961360T ATE309207T1 AT E309207 T1 ATE309207 T1 AT E309207T1 AT 00961360 T AT00961360 T AT 00961360T AT 00961360 T AT00961360 T AT 00961360T AT E309207 T1 ATE309207 T1 AT E309207T1
Authority
AT
Austria
Prior art keywords
protein tyrosine
compounds
phosphate
modulate
expected
Prior art date
Application number
AT00961360T
Other languages
English (en)
Inventor
Ping Huang
Chung Chen Wei
Peng Cho Tang
Chris Liang
John Ramphal
Bahija Jallal
John Biltz
Sharon Li
Matthew Neil Mattson
Gerald Mcmahon
Marcel Koenig
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE309207T1 publication Critical patent/ATE309207T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00961360T 1999-08-27 2000-08-25 Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren ATE309207T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15097099P 1999-08-27 1999-08-27
US16536599P 1999-11-12 1999-11-12
PCT/US2000/023293 WO2001016097A1 (en) 1999-08-27 2000-08-25 Phosphate mimics and methods of treatment using phosphatase inhibitors

Publications (1)

Publication Number Publication Date
ATE309207T1 true ATE309207T1 (de) 2005-11-15

Family

ID=26848202

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961360T ATE309207T1 (de) 1999-08-27 2000-08-25 Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren

Country Status (12)

Country Link
US (2) US6596772B1 (de)
EP (1) EP1212296B9 (de)
JP (1) JP2003508382A (de)
AT (1) ATE309207T1 (de)
AU (1) AU775625B2 (de)
CA (1) CA2382789A1 (de)
DE (1) DE60023920T2 (de)
ES (1) ES2252058T3 (de)
IL (1) IL148243A0 (de)
NZ (1) NZ517426A (de)
WO (1) WO2001016097A1 (de)
ZA (1) ZA200201609B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3208200A (en) 1999-01-13 2000-08-01 Research Foundation Of The State University Of New York, The A novel method for designing protein kinase inhibitors
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US20090124690A1 (en) * 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
WO2003032982A1 (en) * 2001-10-19 2003-04-24 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
JP4623962B2 (ja) * 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
EP1446487A1 (de) * 2001-11-13 2004-08-18 Sugen, Inc. Säuger-protein phosphatasen
US20040014699A1 (en) * 2002-07-18 2004-01-22 Isis Pharmaceuticals, Inc. Antisense modulation of PTPRM expression
JPWO2004039770A1 (ja) * 2002-10-30 2006-03-02 日本曹達株式会社 ジフェニルスルホン誘導体を用いた記録材料及び新規ジフェニルスルホン誘導体化合物
DE10256182A1 (de) * 2002-12-02 2004-06-24 Merck Patent Gmbh 2-Oxadiazolchromonderivate
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
US20040167183A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
AU2003297904A1 (en) * 2003-12-12 2005-07-14 University Of Maryland, Baltimore Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
JP4898458B2 (ja) * 2004-02-12 2012-03-14 トランス テック ファーマ，インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
US20060135483A1 (en) * 2004-07-09 2006-06-22 Cheruvallath Zacharia S Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
ES2318556T3 (es) 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
US8883841B2 (en) * 2005-11-23 2014-11-11 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
AU2007211319B9 (en) 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
JP5190892B2 (ja) * 2006-02-28 2013-04-24 独立行政法人理化学研究所 新規３−（１−アミノアルキリデン）フラン−２，４（３ｈ，５ｈ）−ジオン誘導体、その製造方法、および、これを有効成分とする医薬組成物
EP2004697A2 (de) 2006-04-07 2008-12-24 The Procter & Gamble Company An die humane proteintyrosinphosphatase-beta (hptp-beta) bindende antikörper und anwendungen davon
US20070238700A1 (en) * 2006-04-10 2007-10-11 Winzenberg Kevin N N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
WO2007141926A1 (ja) * 2006-06-02 2007-12-13 Osaka University 延長型アミロイドβ産生抑制剤
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN101506180B (zh) * 2006-06-27 2013-10-30 艾尔普罗医疗有限公司 人蛋白酪氨酸磷酸酶抑制剂及使用方法
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US8119693B2 (en) * 2007-05-08 2012-02-21 Sanford-Burnham Medical Research Institute Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
KR101599715B1 (ko) * 2007-08-21 2016-03-08 세노믹스, 인코포레이티드 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도
WO2009049098A2 (en) * 2007-10-09 2009-04-16 Indiana University Research & Technology Corporation Materials and methods for regulating the activity of phosphatases
EP2227681A4 (de) * 2007-12-31 2011-01-12 Univ California Einzelschritt-echtzeiterkennung von proteinkinase- und/oder phosphatase-aktivitäten aus sers-basis
US7786171B2 (en) * 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
TWI649313B (zh) 2009-06-29 2019-02-01 阿吉歐斯製藥公司 治療化合物及組成物
KR101426125B1 (ko) 2009-07-06 2014-08-06 에르피오 세러퓨틱스 인코포레이티드 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011022462A2 (en) * 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
EP2525790B1 (de) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Verfahren und zusammensetzungen für zellproliferationsbedingte erkrankungen
CA2777304A1 (en) * 2009-10-21 2011-04-28 Marion Hitchcock Substituted benzosulphonamides
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US9199914B2 (en) 2010-02-03 2015-12-01 Meh Associates, Inc. Multiple substituted fluoromethanes as selective and bioactive isosteres
BR112013001122B1 (pt) * 2010-07-16 2021-06-08 Agios Pharmaceuticals, Inc composto de fórmula ii, uso do composto e composição farmacêutica compreendendo dito composto
US20140294805A1 (en) 2010-09-03 2014-10-02 Kenneth W. Bair Novel compounds and compositions for the inhibition of nampt
AU2012219323A1 (en) 2011-02-18 2013-09-05 President And Fellows Of Harvard College Molecular switch for neuronal outgrowth
FI3406251T3 (fi) 2011-05-03 2024-02-21 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattoreita terapeuttista käyttöä varten
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
DK2800743T3 (en) 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10206967B2 (en) 2012-04-09 2019-02-19 Case Western Reserve University Compositions and methods for treating heart disease and/or injury
US10729777B2 (en) 2012-04-09 2020-08-04 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
EP2841086B1 (de) * 2012-04-09 2018-09-26 Case Western Reserve University Zusammensetzungen zur behandlung von nervenverletzung durch hemmung der aktivität der lar-phosphatasefamilie
US10786541B2 (en) 2012-04-09 2020-09-29 Case Western Reserve University Compositions and methods for treating heart disease and/or injury
CA2888360A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
RS58960B1 (sr) 2013-09-09 2019-08-30 Peloton Therapeutics Inc Aril etri i njihova primena
US9884843B2 (en) 2013-12-16 2018-02-06 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
CN106255498B (zh) 2014-03-14 2020-06-26 阿吉奥斯制药公司 治疗活性化合物的药物组合物
US10258672B2 (en) 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
ES2959690T3 (es) 2015-06-11 2024-02-27 Agios Pharmaceuticals Inc Procedimientos de uso de activadores de piruvato cinasa
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
CA3002067C (en) 2015-10-15 2023-11-28 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
SG10202111435UA (en) 2015-10-15 2021-12-30 Les Laboratoires Servier Sas Combination therapy for treating malignancies
EP4302834A2 (de) 2016-07-12 2024-01-10 Revolution Medicines, Inc. 2,5-disubstituierte 3-methyl pyrazine und 2,5,6-trisubstituierte 3-methylpyrazine als allosterische shp2-inhibitoren
KR102348155B1 (ko) * 2016-07-18 2022-01-06 오에이티 아그리오 가부시키가이샤 신규한 벤질아미드 화합물, 이를 제조하는 방법, 및 살진드기제
CA3030680C (en) * 2016-08-19 2021-11-02 Nippon Soda Co., Ltd. Method for producing fluorine-containing sulfonylamide compound
CN106645723A (zh) * 2016-11-04 2017-05-10 中国人民解放军第二军医大学 Shp2蛋白在制备肝癌对索拉菲尼疗效评估试剂盒中的应用
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
WO2018136265A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
MX2020002608A (es) 2017-09-07 2020-09-18 Revolution Medicines Inc Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cáncer.
KR20200070295A (ko) 2017-10-12 2020-06-17 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘, 피라진 및 트리아진 화합물
EP3724189B1 (de) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polyzyklischen verbindungen als allosterischen shp2 hemmer
BR112020021967A2 (pt) 2018-05-03 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. derivados de benzimidazol como moduladores de receptor gama órfão relacionado a retinoides (ror¿) e usos farmacêuticos dos mesmos
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
CN114502535B (zh) * 2019-10-31 2024-04-12 江苏恒瑞医药股份有限公司 一种RORγ调节剂的酸加成盐
WO2021253017A2 (en) * 2020-06-07 2021-12-16 Ramasamy Sundaram Compositions and methods for detoxifying bacterial endotoxins and hydrogen sulfide by recombinant fusion enzymes
CN115637189B (zh) * 2022-11-14 2023-08-29 俄美达（武汉）有限公司 一种基于多孔性碳材的镁合金切削液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758241A (fr) * 1969-11-03 1971-04-30 Agfa Gevaert Nv Bereiding van 2-alkyl-thiazolen en 2-alkyl-selenazolen met een geanelleerde aromatische ring
US4177057A (en) * 1977-10-25 1979-12-04 United States Borax & Chemical Corporation Herbicidal benzimidazoles
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
CA2293400A1 (en) * 1997-06-13 1998-12-17 Gerald Mcmahon Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Also Published As

Publication number Publication date
AU775625B2 (en) 2004-08-05
WO2001016097A1 (en) 2001-03-08
DE60023920T2 (de) 2006-07-20
ES2252058T3 (es) 2006-05-16
EP1212296B1 (de) 2005-11-09
NZ517426A (en) 2004-04-30
EP1212296B9 (de) 2006-05-10
US6596772B1 (en) 2003-07-22
ZA200201609B (en) 2003-07-30
EP1212296A1 (de) 2002-06-12
US20040138255A1 (en) 2004-07-15
CA2382789A1 (en) 2001-03-08
IL148243A0 (en) 2002-09-12
JP2003508382A (ja) 2003-03-04
AU7332100A (en) 2001-03-26
DE60023920D1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
ATE309207T1 (de) Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
DE69737814D1 (de) Gekürzte lösliche typ-i-rezeptoren für tumor-nekrose-faktor
BR9811988A (pt) Derivados de n-alcanoilfenilalanina
MX9606404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
ATE298248T1 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
ATE413386T1 (de) Ppar-gamma modulatoren
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE69830513D1 (de) HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
EP1247803A3 (de) Indolinon-Verbindungen und deren Verwendung als Protein- Kinase-Modulatoren
EP1488792A3 (de) Quinazolinverbindungen mit CSF-1R Rezeptor Tyrosinkinase inhibierender Wirkung
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
EP2409704A3 (de) c-Met-Modulatoren und Verwendungsverfahren
ATE353640T1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
WO2000008202A3 (en) 3-methylidenyl-2-indolinone modulators of protein kinase
PT655890E (pt) Celulas recombinantes, construcoes de adn, vectores e metodos para expressao de enzimas degradantes de fitato em proporcoes desejadas
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
DK1192247T3 (da) Sphingosinkinaseenzym
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
AU2001280812A1 (en) Gsk3 polypeptides
DE69826717D1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO1998024887A3 (en) Parasitic nematode transglutaminase proteins, nucleic acid molecules, and uses thereof
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties